Division of Clinical Pharmacology, Department of Molecular and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Clin Chem. 2011 Aug;57(8):1161-8. doi: 10.1373/clinchem.2011.163006. Epub 2011 Jun 2.
α-1-Antitrypsin (A1AT) deficiency results from a genetic disorder at 2 common loci. Diagnosis requires quantification of A1AT and subsequent identification of the specific variant. The current algorithm of laboratory testing for the diagnosis of A1AT deficiency uses a combination of quantification (nephelometry), genotyping, and/or phenotyping. We developed a multiple reaction monitoring liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of A1AT and identification of the 2 most common deficiency alleles present in 95% of the patients with A1AT deficiency.
Serum samples (n = 40) were digested with trypsin, and appropriate ¹³C/¹⁵N-labeled standard peptides were added. We performed LC-MS/MS analysis with a 0.5- by 150-mm C18 column and H₂O:acetonitrile:n-propanol:formic acid (A:98:1:1:0.2 and B:10:80:10:0.2; flow 12 μL/min) mobile phase in positive ion mode on a TSQ Quantum triple quadrupole MS system. We measured the A1AT concentration by comparison to a calibration curve and determined the phenotype by the presence or absence of variant peptides. We compared the results to the current phenotyping assay by isoelectric focusing (IEF) and the immunonephelometry quantitative assay.
For A1AT allele detection, in 39 of 40 samples the LC-MS/MS results were identical to those obtained by IEF gel electrophoresis. The single discrepant result was rerun by IEF at a lower dilution, and the results were in concordance. The A1AT quantification by LC-MS/MS also compared favorably with nephelometry.
The LC-MS/MS method correlates well with current phenotyping and nephelometric assays and has the potential to improve the laboratory diagnosis of genetic A1AT deficiency.
α-1-抗胰蛋白酶(A1AT)缺乏症是由两个常见基因座的遗传缺陷引起的。诊断需要定量检测 A1AT,并随后确定具体的变异体。目前用于诊断 A1AT 缺乏症的实验室检测算法使用定量(散射比浊法)、基因分型和/或表型分析的组合。我们开发了一种多重反应监测液相色谱-串联质谱(LC-MS/MS)方法,用于同时定量 A1AT 并鉴定 95%的 A1AT 缺乏症患者中存在的 2 个最常见的缺陷等位基因。
用胰蛋白酶消化血清样本(n=40),并加入适当的 ¹³C/¹⁵N 标记标准肽。我们使用 0.5-×150-mm C18 柱和 H₂O:乙腈:n-丙醇:甲酸(A:98:1:1:0.2 和 B:10:80:10:0.2;流速 12 μL/min)在正离子模式下进行 LC-MS/MS 分析,在 TSQ Quantum 三重四极杆 MS 系统上进行。我们通过与校准曲线进行比较来测量 A1AT 浓度,并通过是否存在变异肽来确定表型。我们将结果与目前的等电聚焦(IEF)和免疫散射比浊定量测定的表型分析进行比较。
在 40 个样本中的 39 个样本中,LC-MS/MS 结果与 IEF 凝胶电泳的结果完全一致。唯一不一致的结果在较低稀释度下重新进行 IEF 检测,结果一致。LC-MS/MS 定量 A1AT 与散射比浊法也有很好的相关性。
LC-MS/MS 方法与目前的表型和散射比浊测定法相关性良好,有可能改善遗传 A1AT 缺乏症的实验室诊断。